Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the efficacy and safety of liraglutide added to capped insulin doses in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placebo added to an individually capped total daily dose of insulin. RESULTS: Mean baseline glycated hemoglobin (HbA1c) (8.1% [65.0 mmol/mol]) was significantly decreased with liraglutide versus placebo at week 26 (1.8 mg: –0.33% [3.6 mmol/mol]; 1.2 mg: –0.22% [2.4 mmol/mol]; 0.6 mg: –0.23% [2.5 mmol/mol]; placebo: 0.01% [0.1 mmol/mol]). Liraglutide significantly reduced mean body weight (–5.1, –4.0, and –2.5 kg for 1.8, 1.2, and 0.6 mg, respectively) versus placebo (–0.2 kg). Significant reductions in daily insulin dose and increases in quality of life were seen with liraglutide versus placebo. There were higher rates of symptomatic hypoglycemia (21.3 vs. 16.6 events/patient/year; P = 0.03) with liraglutide 1.2 mg vs. placebo and of hyperglycemia with ketosis >1.5 mmol/L with liraglutide 1.8 mg vs. placebo (0.5 vs. 0.1 events/patient/year; P = 0.01). CONCLUSIONS: In a broad population of subjects with long-standing type 1 diabetes, liraglutide added to capped insulin reduced HbA1c, body weight, and insulin requirements but with higher rates of hypoglycemia for liraglutide 1.2 mg and hyperglycemia with ketosis for liraglutide 1.8 mg.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a potential risk of severe hypoglycemia if persons with DM do not appropriately reduce the prandial insulin dosage.1171–1174”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“The amylin analog pramlintide, the only other medication approved for the treatment of T1D, is administered with prandial insulin.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“A1C reductions are consistently modest, and mild weight loss is common.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“Tachyphylaxis is often seen after several years of therapy.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
In the citing paper
“Nausea is a common adverse effect.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1171]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 4×
“At 26 weeks, significantly more subjects receiving liraglutide 1.8 mg compared with placebo achieved the ADA target of HbA1c,7.0% (,53.0mmol/mol) (18.8 vs. 10.0%, respectively, odds ratio [OR] 2.12 [95% CI 1.11; 4.06], P = 0.0231) (Fig.”
BackgroundInfluentialMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Self-citationon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Health-Related Quality of Life and Treatment Satisfaction in Dutch Patients With Type 2 Diabetes
Redekop, W. K., Koopmanschap, M. A., Stolk, R. P., Rutten, G. E. H. M., Wolffenbuttel, B. H. R., & Niessen, L. W. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.458 · Cited by 565
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537 · cited 1×
“Furthermore, liraglutide decreases food intake (9) and has weight loss benefits in type 2 diabetes (10–14).”
BackgroundBradley, C., & Lewis, K. S. (1990) · Diabetic Medicine · doi:10.1111/j.1464-5491.1990.tb01421.x · Cited by 379
Research works printed but not linked: 3
- FDA, 2005, New diabetes drug, FDA Consum, 39, 3
- 2013, Kidney Disease: Improving Global Outcomes. Definition and classification of CKD, KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl, 3, 19
- Østergaard, 2015, Effects of liraglutide as add-on to insulin on counter-regulatory hormone responses, gastric emptying and glycaemic recovery during hypoglycaemia (Abstract), Diabetologia, 58, A963
Cited by
Items 101–200 of 271
Type 1 Diabetes: Disease Stratification
Insel, R. A., Dutta, S., & Hedrick, J. A. (2017) · Biomedicine Hub · doi:10.1159/000481131 · Cited by 18
Non-insulin pharmacological therapies for treating type 1 diabetes
Frandsen, C. S., Dejgaard, T. F., Madsbad, S., & Holst, J. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1483339 · Cited by 18
“[50,51] Additionally, from animal and in vitro human models, there is evidence that GLPRAs preserve beta-cells from destruction [109,110], which has led to the initiation of interesting ongoing trials in newonset T1D.”
BackgroundEmpagliflozin in type 1 diabetes
Mathieu, C., den Mooter, L. V., & Eeckhout, B. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s194688 · Cited by 19
“The ADJUNCT program confirmed the beneficial effects on weight, but also demonstrated that glucose lowering, although robust, was transient and accompanied by an increase in (severe) hypoglycemic events and increased risk of ketosis.(5,6)”
BackgroundSelf-citationNeumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad285 · Cited by 18
Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy
Pasqua, M., Tsoukas, M. A., & Haidar, A. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211035411 · Cited by 18
Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonists in T1DM Patients
Mohandas, D., Calma, J., Gao, C., & Basina, M. (2023) · Endocrines · doi:10.3390/endocrines4010008 · Cited by 19
Potential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow?
Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01506-1 · Cited by 16
Xu, Y., Echouffo Tcheugui, J. B., Coresh, J., Grams, M. E., Selvin, E., Fang, M., & Shin, J. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16300 · Cited by 15
“41,42 However, these benefits were accompanied by increased risks of symptomatic hypoglycaemia and hyperglycaemia with ketosis with use in type 1 diabetes.”
Kidney Disease: The Forgotten Legacy of Type 1 Diabetes
Thomas, M. C., Zoungas, S., Hanssen, N. M. J., McAuley, S. A., & Cooper, M. E. (2025) · Diabetes Care · doi:10.2337/dci25-0028 · Cited by 20
Incretins beyond type 2 diabetes
Mathieu, C., & Ahmadzai, I. (2023) · Diabetologia · doi:10.1007/s00125-023-05980-x · Cited by 17
Self-citationDoggrell, S. A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1519547 · Cited by 16
“On randomization, the dose of insulin was reduced as in ADJUNCT ONE [36].”
BackgroundMethodInfluentialEdwards, K., Uruska, A. A., Duda‐Sobczak, A., Zozulińska‐Ziółkiewicz, D., & Lingvay, I. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231180987 · Cited by 15
Albèr, A., Brønden, A., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12911 · Cited by 14
“glycaemic control at the cost of increased risk of hypoglycaemic and hyperglycaemic events.(46,47) In contrast to the long-acting GLP-1RAs, the short-acting GLP-1RAs exhibit sustained retardation of gastric”
BackgroundJohansen, N. J., Dejgaard, T. F., Lund, A., Schlüntz, C., Larsen, E. L., Poulsen, H. E., Goetze, J. P., Møller, H. J., Vilsbøll, T., Andersen, H. U., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14078 · Cited by 14
Double Diabetes: A Growing Problem Requiring Solutions
Popovic, D. S., & Παπάνας, Ν. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1392-0590 · Cited by 14
Recent developments in adjunct therapies for type 1 diabetes
Timmons, J. G., Littlejohn, L., Boyle, J. G., & Petrie, J. R. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2159806 · Cited by 17
“The largest randomized control trials to date investigating GLP-1RAs in T1D are the ADJUNCT ONE [91] and ADJUNCT TWO [92] trials.”
BackgroundInfluentialAl‐Ozairi, E., Irshad, M., Alkandari, J., SOJAN, L. G., Alroudhan, D., Alotaibi, N., & le Roux, C. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70172 · Cited by 14
“24,25 While most cardiovascular data are available for people with obesity and T2D, our findings are also consistent with those of the LEADER trial; the latter demonstrated reduced cardiovascular risk with liraglutide compared to placebo.”
STOUGAARD, E. B., Andersen, M. R., Bagger, J. I., Søndergaard, E., Østergaard, J. A., Curovic, V. R., Persson, F., Almdal, T., Mathiesen, A. S., Andries, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16606 · Cited by 14
“46,48 Finerenone on top of maximum tolerated RAS-blockade has showed reductions in the risk of kidney and CV composite outcomes in individuals with CKD and albuminuria.”
Pharmacological therapies to address obesity in type 1 diabetes
Casu, A., Bilal, A., & Pratley, R. E. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000555 · Cited by 16
Incretins: B eyond type 2 diabetes
Dandona, P., Ghanim, H., & Chaudhuri, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13153 · Cited by 14
“3% when compared to the placebo.(66,67) There was also a reduction in body weight in both (Table 1).”
Alternative therapeutic strategies in diabetes management
Annicchiarico, A., Barile, B., Buccoliero, C., Nicchia, G. P., & Brunetti, G. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i6.1142 · Cited by 14
Unveiling the Disparities in the Field of Precision Medicine: A Perspective
Morsi, M. H., Elawfi, B., ALsaad, S. A., Nazar, A., Mostafa, H. A., Awwad, S. A., Abdelwahab, M. M., Tarakhan, H., & Baghagho, E. (2025) · Health Science Reports · doi:10.1002/hsr2.71102 · Cited by 12
“As an addition to insulin, the GLP ‐ 1 analog liraglutide lowers HbA1c and decreases body weight in type 1 diabetes [16].”
Purcell, A. R., Zhen, X. M., Wong, J., & Glastras, S. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70188 · Cited by 13
Individualized diabetes care: Lessons from the real-world experience
Khor, X. Y., Pappachan, J. M., & Jeeyavudeen, M. S. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i13.2890 · Cited by 13
Jones, A. G., Shields, B. M., Oram, R. A., Dabelea, D., Hagopian, W., Sharp, S. A., Lustigova, E., SHAH, A. S., Knupp, J., Mottl, A. K., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1815 · Cited by 12
Shah, V. N., Agesen, R. M., Bardtrum, L., Christiansen, E., SNAITH, J. R., & Greenfield, J. R. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241305647 · Cited by 11
“28,29 To our knowledge, no studies have examined the factors affecting intolerability or increased risk for side effects leading to drug discontinuation of GLP-1 RA in individuals with T1D.”
InfluentialSelf-citationPodobnik, J., & Prentice, K. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16154 · Cited by 15
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 14
“60 64 These benefits must be balanced against the risk of hypoglycemia and, in some cases, diabetic ketoacidosis if insulin is inappropriately reduced.”
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · BMC Medicine · doi:10.1186/s12916-020-01787-4 · Cited by 12
Abu‐Zaid, A., Altowairqi, A. K., Dissanayaka, T. D., Oganesyan, A., Bhagavathula, A. S., Alhabeeb, H., Baradhwan, A., Alomar, S. A., & Tom, S. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105456 · Cited by 12
Klein, K. R., BOEDER, S. C., Freeman, J. L. R., Dunn, I. M., Dvergsten, C., Madduri, S. S., Giovannetti, E. R., Valcarce, C., Buse, J. B., & Pettus, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14697 · Cited by 11
Self-citationde Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., Sadusky, T., et al. (2025) · Kidney International · doi:10.1016/j.kint.2024.12.019 · Cited by 12
REDONDO, M. J., & Bacha, F. F. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa314 · Cited by 10
Zenz, S., Regittnig, W., Boulgaropoulos, B., Augustin, T., Brunner, M., Korsatko, S., Münzker, J., Narath, S. H., Raml, R., Magnes, C., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac369 · Cited by 11
Self-citationSGLT inhibitors for people with type 1 diabetes
Llano, A., McKay, G., & Fisher, M. (2019) · Practical Diabetes · doi:10.1002/pdi.2222 · Cited by 10
Adjunctive therapies in type 1 diabetes mellitus
Lane, K. L., & Freeby, M. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000602 · Cited by 12
“Early RCTs, ADJUNCT ONE and TWO, compared adjunctive liraglutide with placebo in individuals with type 1 diabetes on insulin [20,21].”
BackgroundAberer, F., Pieber, T. R., Eckstein, M. L., Sourij, H., & Moser, O. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061180 · Cited by 12
“8 mg) in two phase three trials comprising more than 2000 persons with T1D [62,63].”
BackgroundSelf-citationAng, K. H., & Sherr, J. L. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1360862 · Cited by 11
“Importantly, quality of life was reported to be improved with use of liraglutide as compared to placebo [47].”
BackgroundResultInfluentialAdjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes
Isaacs, D. M., Yager, S., Parker, M., Wolfe, L., Luxenburg, J., & Lekic, S. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018816728 · Cited by 10
Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes
Fang, M., Echouffo-Tcheugui, J. B., & Selvin, E. (2023) · Annals of Internal Medicine · doi:10.7326/l23-0228 · Cited by 10
The effects of GLP-1 agonists on HbA1c and insulin dose among patients with type 1 diabetes
Alhowiti, A., & Mirghani, H. O. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1550938 · Cited by 10
Seetharaman, S., & Cengiz, E. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241305641 · Cited by 9
“10,11 In this case series, one patient (case 8) experienced an increase in hypoglycemic episodes, necessitating a decrease in insulin dose.”
Seetharaman, S., & Cengiz, E. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241309896 · Cited by 9
“26”
Ballav, C., Dhere, A., Kennedy, I., Agbaje, O. F., White, S. J., Franklin, R. H., Hartmann, B., Holst, J. J., Holman, R. R., & Owen, K. R. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.130 · Cited by 10
Ruddiman, K. R., Bartfield, J. K., & Hirsch, I. B. (2025) · Obesity · doi:10.1002/oby.70033 · Cited by 10
Self-citationAdvances in alginate encapsulation of pancreatic islets for immunoprotection in type 1 diabetes
Chaudhary, D., Nguyen, T. T., Yook, S., & Jeong, J. (2023) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-023-00627-w · Cited by 9
“Similarly, 1 3 types of glucagon-like peptide-1 (GLP-1) such as exenatide, lixisenatide, and liraglutide are also under investigation for adjuvant of T1D treatment (Ryan et al. 2009; Ahrén et al. 2016; Goyal et al. 2020; Dejgaard et al. 2021; Lane and Freeby 2021).”
BackgroundLamaro, B. D., Greenfield, J. R., & SNAITH, J. R. (2024) · Journal of Patient Experience · doi:10.1177/23743735241257811 · Cited by 10
“12,13 Upon survey completion, respondents were invited to participate in individual interviews for Study B.”
MethodHirsch, I. B., Parkin, C. G., Cavaiola, T. S., & Bergenstal, R. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15883 · Cited by 8
“52”
InfluentialSelf-citationSTOUGAARD, E. B., Curovic, V. R., & Hansen, T. W. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01726-7 · Cited by 11
“The use of GLP1-RA in type 1 diabetes has shown to increase the risk of hyperglycemia and ketosis, which has also led to concerns of DKA [48, 60, 61].”
Self-citationTreatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 9
Mertens, J., Winter, H. T. D., Dirinck, E. L., Francque, S., & Block, C. E. M. D. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251362497 · Cited by 12
Abdel‐Rahman, S. M., Al-Shiab, R., Shah, E., Güldan, M., Ak, A. B., Yilmaz, Z. Y., Fidan, D. G., Özbek, L., & Kanbay, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70506 · Cited by 7
Garg, S. K., Aktürk, H. K., Garg, S., Beck, R. W., Bellini, N. J., Bjornstad, P., Carlson, A. L., Carroll, J., Close, K., Block, C., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261449879 · Cited by 8
Self-citationUse of GLP-1 Receptor Agonists for the Management of Type 1 Diabetes: A Pediatric Perspective
Nevo-Shenker, M., & Shalitin, S. (2024) · Hormone Research in Paediatrics · doi:10.1159/000541228 · Cited by 9
Dapagliflozin for the treatment of type 1 diabetes mellitus
Pafili, K., Maltezos, E. S., & Παπάνας, Ν. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1339788 · Cited by 7
Qiu, L., Ling, P., Yang, D., Luo, S., Zheng, X., Liang, H., Yuan, Y., Liang, G., Xu, W., Yao, B., et al. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13025 · Cited by 8
“03 nmol/L).(33,34) Previous studies showed that dipeptidyl peptidase IV inhibitors added to insulin reduced the daily insulin requirement without increasing the risk of hypoglycemia in patients with T1DM, but the effect on HbA1c was inconsistent.”
BackgroundGarg, S., Kim, S., Ford, A. M., Loesch, J., Valencia, S. O., Zhou, K., & Lembo, A. J. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251403555 · Cited by 7
Safety of GLP-1 receptor agonists in type 1 diabetes: a systematic review and meta-analysis.
Kateel, R., Parida, A., Chogtu, B., & Holla, S. N. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113270 · Cited by 6
Rajab, A. M., Pearson, S. M., & Ajjan, R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16332 · Cited by 6
“Liraglutide significantly reduced HbA1c by 0.3% – 0.5% compared to placebo, 110,111 while significantly reducing mean body weight by (cid:2) 2.2 to (cid:2) 5.1 kg, effects which were dose-dependent.”
InfluentialSaeed, Z. I., Aktürk, H. K., Aleppo, G., Kruger, D. F., Levy, C. J., Mader, J. K., Sherr, J. L., & Shah, V. N. (2024) · Clinical Diabetes · doi:10.2337/cd24-0067 · Cited by 8
Rebelos, E., Anastasiou, I. A., Tentolouris, N., Karagiannis, T., Τσάπας, Α., Ferrannini, E., & Liakos, A. (2025) · HORMONES · doi:10.1007/s42000-025-00704-9 · Cited by 8
“Nine studies included either patients with new onset of T1D or with detectable C-peptide levels [21, 22, 26, 31, 34, 35, 43] and were considered having preserved β-cell function.”
Chen, J., Fan, L., Peng, X., Ilag, L. L., Ly, T. T., & Johnson, J. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14191 · Cited by 6
Noninsulin Therapies in Management of Type 1 Diabetes
Saeed, Z. I., Ambalavanan, J., Rayan, M. N., Patadia, P., & Shah, V. N. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.027 · Cited by 7
Wu, Y., Lu, Y., Yang, S., & Zhang, Q. (2021) · Journal of International Medical Research · doi:10.1177/03000605211066306 · Cited by 6
“Ahr en et al.(12) found no significant difference in mean plasma C-peptide levels between patients with T1DM with detectable C-peptides treated with any liraglutide dose and placebo at 26 weeks.”
BackgroundJoshi, N., Baloch, K. M., Rukh, S., Khan, A. M., Muskan, F., Kumari, V., Khan, H., Zeeshan, M., Azam, G., Khalid, S., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002712 · Cited by 6
Interventions Targeting Insulin Resistance in Patients with Type 1 Diabetes: A Narrative Review
Herascu, A., Avram, V. F., Gaiţă, L., Sima, A. C., Reurean‐Pintilei, D., & Timar, B. (2024) · Medicina · doi:10.3390/medicina60122067 · Cited by 6
Melander, S. A., Larsen, A. T., Karsdal, M. A., & Henriksen, K. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16329 · Cited by 6
Vendrame, F., Calhoun, P. M., Bocchino, L. E., Pratley, R. E., & Casu, A. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107884 · Cited by 5
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Frampton, R., HOCKING, S. L., SNAITH, J. R., & Greenfield, J. R. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.06.004 · Cited by 4
van Laar, A., Gallardo‐Nuell, L., Pazmiño, S., Visser, M. M., Mertens, A. C., Vangoitsenhoven, R., Gillard, P., Al‐Ozairi, E., le Roux, C. W., Rosen, J., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103589 · Cited by 4
Self-citationPasqua, M., Tsoukas, M. A., & Haidar, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70213 · Cited by 5
Tentolouris, A., Koufakis, T., & Fousteris, E. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00693-9 · Cited by 5
“At week 26, liraglutide significantly reduced HbA1c versus placebo (mean change: −0.33% with 1.8 mg compared with 0.01% with placebo) and produced clinically meaningful weight loss (−5.1 kg with 1.8 mg versus − 0.2 kg with placebo) [ 81 ].”
InfluentialEmerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials
Min, T., & Bain, S. C. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2188191 · Cited by 4
“ADJUNCT ONE, a 52week, phase 3, double-blind, treat-to-target trial with 1398 participants [112] and ADJUNCT TWO, a 26-week phase 3, RCT with 835 participants [113], investigated the efficacy and safety of three liraglutide doses (0.”
BackgroundNegi, V., Lee, J., Mandi, V., Danvers, J., Liu, R., Perez-Garcia, E. M., Li, F., Jagannathan, R., Yang, P., Filingeri, D., et al. (2024) · Cells · doi:10.3390/cells13131108 · Cited by 5
“Although it is approved to be used only in patients with T2D, and not T1D, some studies show benefits with potential risks with GLP-1R agonists in T1D [9–12].”
BackgroundHundert Jahre – Insulin bleibt aktuell und notwendig
Landgraf, R., & Aberle, J. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1386-0011 · Cited by 8
“In der ADJUNCT-TWO-Studie (n = 835), die über 26 Wochen ausgelegt war [65], führte Liraglutid in Kombination mit Insulin zu einer Reduktion des HbA1c-Werts um 0,2–0,3 % bei gleichzeitiger Insulindosisreduktion vorwiegend des prandialen Insulins um 3–6 E/täglich.”
BackgroundPrevention of type 1 diabetes: where we are and where we are going
Frontino, G., GUERCIO, N. S., SCARAMUZZA, A., D’ANNUNZIO, G., Toni, S., CITRINITI, F., & Bonfanti, R. (2021) · Minerva Pediatrics · doi:10.23736/s2724-5276.21.06529-0 · Cited by 4
Aung, N. L. (2024) · Clinical Diabetes · doi:10.2337/cd24-0038 · Cited by 5
The role of GLP1 receptor agonists in adult-onset type 1 diabetes mellitus
Popovic, D. S., Koufakis, T., Patoulias, D., Maltese, G., & Παπάνας, Ν. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01154-4 · Cited by 3
“…its place within the treatment algorithm of T1DM. participants in all liraglutide dose groups had an improved treatment effect on HbA 1c compared with C-peptide-negative participants, and only one individual with measurable C-peptide experienced one episode of hyperglycaemia with ketosis 7 .”
The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults
Lunati, M. E., Cimino, V., Bernasconi, D. P., Romano, C., Disoteo, O., Rossi, A., Tinari, C., Fiorina, R. M., Gandolfi, A., Morpurgo, P. S., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag072 · Cited by 4
Tentolouris, A., Filippatos, C., Tepetes, N.-I., Gavriatopoulou, M., Terpos, E., Briasoulis, Α., Stamatelopoulos, K. S., & Filippatos, T. D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70841 · Cited by 4
“GLP- 1-based therapies have been evaluated as adjunct treat-ment in adults with T1D in several RCTs, showing modest HbA1c improvements, consistent weight loss, and reductions in insulin requirements, albeit with safety concerns [16–21].”
InfluentialGlucagon-like peptide-1 and impaired counterregulatory responses to hypoglycemia in type 1 diabetes
Rocha, G. R., & de Melo, F. F. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.99928 · Cited by 4
Johansen, N. J., Dejgaard, T. F., Lund, A., Vilsbøll, T., Andersen, H. U., & Knop, F. K. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-021861 · Cited by 3
Non-insulin therapies in addition to insulin in Type 1 DM treatment
Llano, A., & McKay, G. A. (2020) · British Medical Bulletin · doi:10.1093/bmb/ldaa011 · Cited by 3
Ning, X., Munir, K. M., & Davis, S. N. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2439501 · Cited by 2
“The investigators were not able to define a clear reason for the hypoglycemia observed for the liraglutide 1.2 mg treated group, however, they did postulate that the increased rate of ketosis may be due to the decreased total insulin daily dose in the liraglutide 1.8 mg treated group [29].”
InfluentialGLP-1 agonists in Type 1 diabetes – Indications and use
Panjawatanan, P., & Comi, R. J. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100591 · Cited by 3
Lisco, G., Tullio, A. D., Disoteo, O., Armigliato, M., Guastamacchia, E., Marucci, S., Pergola, G. D., Papini, E., Chianelli, M., Frasoldati, A., et al. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70073 · Cited by 2
“The ADJUNCT TWO trial results confirmed the efficacy of Liraglutide, especially at 1.8 mg/day, when compared to placebo in improving glucose control and reducing body weight and insulin requirement [78].”
InfluentialWang, W. T., & Loh, W. J. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000940 · Cited by 2
Sánchez-García, D., Luna‐Garza, Y., Saavedra-Castillo, E., Gómez-Martínez, G., Diaz-Sallas, M., Ortega‐Valdez, A. C., Martínez‐Mendoza, Z. F., Reyes‐Valdez, K. R., Huitron‐Ramirez, R. A., Martinez‐Rentería, J. P., et al. (2026) · Diabetic Medicine · doi:10.1111/dme.70222 · Cited by 2
GLP-1 and GIP in Type 1 Diabetes Therapy: A Time for Reappraisal?
Piras, G., Brasili, S., Demontis, D., Sala, L. D., Cocchiara, F., Maggi, D. C., & Arecco, A. (2026) · Diabetology · doi:10.3390/diabetology7030050 · Cited by 2
Mirghani, H. O., Albishi, L. A., & Alblewi, S. M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1758755 · Cited by 2
New and emerging therapies in type 1 diabetes mellitus
Herold, K. C., & Evans‐Molina, C. (2026) · Journal of Clinical Investigation · doi:10.1172/jci205520 · Cited by 4
“Three studies showed benefits of liraglutide or exenatide for patients with established T1D who had residual β cell function but increased rates of hypo-glycemia (64–66).”
Tirzepatide for Excess Weight in Adults With Type 1 Diabetes Using MiniMed 780G
Fano, M. D., Tortoriello, R., Rucco, S., Corio, S., Manco, M., Guerrini, E., & Porcellati, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71002 · Cited by 2
“Although early studies with liraglutide raised concerns regarding hypoglycaemia and ketosis [4, 5], more recent evidence from real-world [6, 7] and a randomised-controlled trial (RCT) [8] suggests that semaglutide may provide clinically meaningful benefits with an acceptable safety profile in…”
Matson, R. P., Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · Diabetology · doi:10.3390/diabetology7100189
The 80th annual (virtual) conference of the American Diabetes Association: June 12–16, 2020
Suliman, M., Mohammed, N., & Suliman, S. (2020) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.4103/ijmbs.ijmbs_106_20 · Cited by 2
“The drugs studied in this group included liraglutide (in the ADJUNCT trials),[10,11] albiglutide, and exenatide.”
BackgroundPasqua, M., Odabassian, M., Tsoukas, M. A., & Haidar, A. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231176302 · Cited by 2
“27 SGLT inhibitors are not the only adjunctive agents to improve the quality of life, as a pilot study using metformin 28 and larger studies using liraglutide 29,30 showed improved treatment satisfaction in questionnaires.”
BackgroundNgan, J., O'Neal, D. N., Lee, M. H., Kong, Y. W., & MacIsaac, R. J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112284 · Cited by 2
Finerenone in type 1 diabetes and chronic kidney disease: short-term efficacy and safety insights
Qiu, D., Wang, J., Li, A., Zhang, W., Du, X., Wang, G., & Jiang, S. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04773-y · Cited by 2
“Clinical translation through the ADJUNCT ONE and TWO trials demonstrated improved glycemic control and body weight reduction [29, 30], though their renal outcomes in T1D remain insufficiently characterized.”
Yamada, T., Mori, R., Hosoe, J., Shojima, N., Kamata, R., Ishinohachi, K., Yamauchi, T., Tanikawa, Y., & Kadowaki, T. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013164 · Cited by 2
Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?
Aeng, E. S. Y., Boucher, M., & Severn, M. (2016) · Cited by 2
Role of Noninsulin Therapies in the Treatment of Type 1 Diabetes
Lingow, S. E., Burke, S. D., Brooks, A. D., & Rafferty, P. S. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0058 · Cited by 2
“Autoimmune pancreatic β-cell destruction ultimately results in an absolute insulin deficiency, the presence of autoimmune markers, and little to no residual C-peptide (2,3).”
BackgroundMethodInfluential
Metadata
- Authors
- Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., Buse, J. B., & for the ADJUNCT TWO Investigators
- Affiliations
- Lund University, Lund, Sweden
- University of Washington (US)
- Medical University of Graz (AT)
- KU Leuven (BE)
- Hospital General de Segovia, Segovia, Spain
- Aarhus University Hospital (DK)
- University of Cape Town (ZA)
- Novo Nordisk (Denmark) (DK)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-08-04
- Volume
- 39
- Issue
- 10
- Pages
- 1693-1701
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2494601841
- Cited by
- 262
- References
- 36
- Citations by year
- 2026: 38 · 2025: 49 · 2024: 33 · 2023: 25 · 2022: 16 · 2021: 23 · 2020: 29 · 2019: 11 · 2018: 21 · 2017: 10 · 2016: 7
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- UNC Libraries
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- liraglutide, type 1 diabetes, GLP-1 receptor agonists, HbA1c, glycemic control, weight loss, insulin dose reduction, hypoglycemia, diabetic ketoacidosis, quality of life
- MeSH terms
- Liraglutide, Adolescent, Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Male, Middle Aged, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.